Products & Launches News

New products, services, launches, and product-related updates.

SLSSELLAS Life Sciences Group, Inc.

SELLAS Says Phase 3 REGAL Trial of GPS Cancer Vaccine Meets Primary Endpoint

SELLAS Life Sciences Group said its pivotal Phase 3 REGAL study of galinpepimut-S (GPS), an investigational immunotherapeutic cancer vaccine, met its primary endpoint in patients with acute myeloid leukemia. According to the company, GPS produced a statistically significant and clinically relevant 41% reduction in the risk of death, with median overall survival that was longer than that seen with the best available treatment.

4 stories